GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rebus Hldgs Inc (OTCPK:RBSH) » Definitions » Market Cap

Rebus Hldgs (Rebus Hldgs) Market Cap : $0.00 Mil (As of May. 01, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Rebus Hldgs Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Rebus Hldgs's share price for the quarter that ended in Jun. 2023 was $0.0155. Rebus Hldgs's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 32.13 Mil. Therefore, Rebus Hldgs's market cap for the quarter that ended in Jun. 2023 was $0.50 Mil.

Rebus Hldgs's quarterly market cap increased from Dec. 2022 ($0.24 Mil) to Mar. 2023 ($0.39 Mil) and increased from Mar. 2023 ($0.39 Mil) to Jun. 2023 ($0.50 Mil).

Rebus Hldgs's annual market cap declined from Dec. 2020 ($1.13 Mil) to Dec. 2021 ($0.31 Mil) and declined from Dec. 2021 ($0.31 Mil) to Dec. 2022 ($0.24 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rebus Hldgs's Enterprise Value for Today is $0.31 Mil.


Rebus Hldgs Market Cap Historical Data

The historical data trend for Rebus Hldgs's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rebus Hldgs Market Cap Chart

Rebus Hldgs Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.10 1.13 0.31 0.24

Rebus Hldgs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.57 0.24 0.39 0.50

Competitive Comparison of Rebus Hldgs's Market Cap

For the Biotechnology subindustry, Rebus Hldgs's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rebus Hldgs's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rebus Hldgs's Market Cap distribution charts can be found below:

* The bar in red indicates where Rebus Hldgs's Market Cap falls into.



Rebus Hldgs Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Rebus Hldgs's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$0.0075*32.1329
=$0.24

Rebus Hldgs's Market Cap for the quarter that ended in Jun. 2023 is calculated as

Market Cap (Q: Jun. 2023 )=Share Price (Q: Jun. 2023 )*Shares Outstanding (EOP) (Q: Jun. 2023 )
=$0.0155*32.1329
=$0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rebus Hldgs  (OTCPK:RBSH) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Rebus Hldgs Market Cap Related Terms

Thank you for viewing the detailed overview of Rebus Hldgs's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Rebus Hldgs (Rebus Hldgs) Business Description

Traded in Other Exchanges
N/A
Address
2629 Townsgate Road, Suite 215, Westlake Village, CA, USA, 91361
Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Executives
John Robison Montgomery director 7647 BIRCHWOOD HILL RD, CROZET VA 22932
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
Claire Thom director 31200 VIA COLINAS, #200, WESTLAKE VILLAGE CA 91362
Ronald L Shazer officer: Chief Medical Officer C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Christopher P. Lowe director, officer: President and CEO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Scott Varde Ogilvie director 10880 WILSHIRE BLVD, SUITE 950, LOS ANGELES CA 90024
Bo Jesper Hansen director BIRKENWEG 16, MEGGEN V8 6045
Peter E Grebow director 41 MOORES ROAD, FRAZER PA 19355
Craig A Dionne director, 10 percent owner, officer: CEO,CFO, President 9901 IH 10 WEST, SUITE 800, SAN ANTONIO TX 78230
Russell Richerson 10 percent owner, officer: COO, Secretary 2511 N LOOP 1604 W, SUITE 204, SAN ANTONIO TX 78258
Kihong Kwon 10 percent owner 1015 E. CHAPMAN AVE, SUITE 201, FULLERTON CA 92831